In the final days of the Biden administration, the U.S. Department of Health and Human Services’ Centers for Medicare and Medicaid Services (CMS) laid out the latest 15 drugs that are subject to negotiated prices,

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. The CMS listed Ozempic, Rybelsus and Wegovy — all forms of

U.S. division has sued CMS over the Medicare drug pricing negotiations policy included in the Inflation Reduction Act. In its lawsuit filed in D.C. federal court, the Israel-based drugmaker says that guidance CMS has issued on price negotiations "gives the agency even more unchecked price-setting power